Lung Cancer
Volume 70, Issue 1 , Pages 1-6 , October 2010

Imaging in pleural mesothelioma: A review of Imaging Research Presented at the 9th International Meeting of the International Mesothelioma Interest Group

  • Anna K. Nowak

      Affiliations

    • School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia
    • Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
    • Corresponding Author InformationCorresponding author at: School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia. Tel.: +61 8 9346 2098; fax: +61 8 9346 2816.
    • ,
  • Samuel G. Armato III

      Affiliations

    • Department of Radiology, The University of Chicago, Chicago, IL, USA
    • ,
  • Giovanni Luca Ceresoli

      Affiliations

    • Department of Medical Oncology and Hematology, Istituto Clinico Humanitas IRCCS, Rozzano (Milan), Italy
    • ,
  • Huseyin Yildirim

      Affiliations

    • Eskisehir Osmangazi University, Medical Faculty, Department of Chest Disease, Meselik, 26480, Eskisehir, Turkey
    • ,
  • Roslyn J. Francis

      Affiliations

    • School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia
    • Department of Nuclear Medicine and WA PET Service, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia

Received 30 October 2009 ,Revised 29 April 2010 ,Accepted 17 May 2010.

References 

  1. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15:257–260
  2. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–216
  3. Zervos MD, Bizekis CPass HI. Malignant mesothelioma 2008. Curr Opin Pulm Med. 2008;14:303–309
  4. Metintas M, Ucgun I, Elbek O, Erginel S, et al. Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases. Eur J Radiol. 2002;41:1–9
  5. Chakrabarti B, Ryland I, Sheard J, Warburton CJ, Earis JE. The role of Abrams percutaneous pleural biopsy in the investigation of exudative pleural effusions. Chest. 2006;129:1549–1555
  6. Heilo A, Stenwig AE, Solheim OP. Malignant pleural mesothelioma: US-guided histologic core-needle biopsy. Radiology. 1999;211:657–659
  7. Adams RF, Gray W, Davies RJ, Gleeson FV. Percutaneous image-guided cutting needle biopsy of the pleura in the diagnosis of malignant mesothelioma. Chest. 2001;120:1798–1802
  8. Metintas M, Ozdemir N, Isiksoy S, Kaya T, et al. CT-guided pleural needle biopsy in the diagnosis of malignant mesothelioma. J Comp Assist Tom. 1995;19:370–374
  9. Scagliotti GV, Novello S. State of the art in mesothelioma. Ann Oncol. 2005;16(Suppl 2):ii240–ii245
  10. Heelan RT, Rusch VW, Begg CB, Panicek DM, et al. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. Am J Roentgenol. 1999;172:1039–1047
  11. Duysinx B, Nguyen D, Louis R, Cataldo D, et al. Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging. Chest. 2004;125:489–493
  12. Kramer H, Pieterman RM, Slebos DJ, Timens W, et al. PET for the evaluation of pleural thickening observed on CT. J Nucl Med. 2004;45:995–998
  13. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16:145–152
  14. Herndon JE, Green MR, Chahinian AP, Corson JM, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113:723–731
  15. Fennell DA, Parmar A, Shamash J, Evans MT, et al. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol. 2005;23:184–189
  16. Francart J, Vaes E, Henrard S, Legrand C, et al. A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials. Eur J Cancer. 2009;45:2304–2311
  17. Boucek JA, Francis RJ, Jones CG, Khan N, et al. Assessment of tumour response with (18)F-fluorodeoxyglucose positron emission tomography using three-dimensional measures compared to SUVmax—a phantom study. Phys Med Biol. 2008;53:4213–4230
  18. Francis RJ, Byrne MJ, van der Schaaf AA, Boucek JA, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med. 2007;48:1449–1458
  19. Armato SG, Ogarek JL, Starkey A, Vogelzang NJ, et al. Variability in mesothelioma tumor response classification. Am J Roentgenol. 2006;186:1000–1006
  20. Oxnard GR, Armato SG, 3rdKindler HL. Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. Lung Cancer. 2006;52:141–148
  21. Ceresoli GL, Chiti A, Zucali PA, Rodari M, et al. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J Clin Oncol. 2006;24:4587–4593
  22. Schaefer NG, Veit P, Steinert H, Stahel RA. Response evaluation by CT and FDG-PET/CT in malignant pleural mesothelioma. J Clin Oncol. 2008;26:Abs 11098

PII: S0169-5002(10)00231-X

doi: 10.1016/j.lungcan.2010.05.016

Lung Cancer
Volume 70, Issue 1 , Pages 1-6 , October 2010

Article Tools

* Image Usage & Resolution